@article{discovery10179018,
           pages = {1--7},
            note = {This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.},
          volume = {30},
         journal = {Amyloid},
           title = {A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis},
            year = {2023},
       publisher = {Informa UK Limited},
           month = {May},
          number = {3},
        keywords = {AL Amyloidosis, Carfilzomib, KTD},
          author = {Ravichandran, Sriram and Hall, Andrew and Jenner, Matthew and Garg, Mamta and Kishore, Bhuvan and Lachmann, Helen and Gillmore, Julian and Pitchford, Alexandra and Oughton, Jamie B and Mahmood, Shameem and Sachchithantham, Sajitha and Hawkins, Philip and Brown, Sarah and Wechalekar, Ashutosh},
        abstract = {INTRODUCTION: Proteasome inhibitors are the backbone of AL amyloidosis treatment - bortezomib being most widely used. Carfilzomib is a proteasome inhibitor licenced to treat multiple myeloma; autonomic and peripheral neuropathy are uncommon toxicities with carfilzomib. There is limited data on the use of carfilzomib in AL amyloidosis. Here, we report the results of a phase Ib dose-escalation study of Carfilzomib-Thalidomide-Dexamethasone (KTD) in relapsed/refractory AL amyloidosis. RESULTS: The trial registered 11 patients from 6 UK centres from September 2017 to January 2019; 10 patients received at least one dose of trial treatment. 80 adverse events were reported from 10 patients in the 1st three cycles. One patient experienced dose-limiting toxicity (acute kidney injury) at a dose of 45 mg/m2, and another patient had a SAR (fever). Five patients experienced an AE {$\ge$} grade 3. There were no haematologic, infectious, or cardiac AE {$\ge$} grade 3. The overall haematological response rate (ORR) at the end of three cycles of treatment was 60\%. CONCLUSION: Carfilzomib 45 mg/m2 weekly can be safely given with thalidomide and dexamethasone. The efficacy and tolerability profile appears comparable to other agents in relapsed AL amyloidosis. These data provide a framework for further studies of carfilzomib combinations in AL amyloidosis.},
             url = {https://doi.org/10.1080/13506129.2023.2169124}
}